Widened Scope of Drug Repurposing/Chiral Switches, Elements of Secondary Pharmaceuticals: The Quinine/Quinidine Case

References

• Knollmann BC, Roden DM, Murray KT. Antiarrhythmic drugs. In: Goodman & Gilman’s: The Pharmacological Basis of Therapeutics (14th Edition).Brunton LL, Knollmann BC (Eds). McGraw Hill, NY, USA, 667–694 (2023).
   Google Scholar
• Djimde AA, Taylor SM. Chemotherapy of malaria. In: Goodman & Gilman’s: The Pharmacological Basis of Therapeutics (14th Edition).Brunton LL, Knollmann BC (Eds). McGraw Hill, NY, USA, 1289–1306 (2023).
   Google Scholar
• The Nobel Committee for Chemistry. Scientific background on the Nobel Prize in Chemistry 2021. Enamine and iminium ion-mediated organocatalysis. The Royal Swedish Academy of Sciences (6 October 2021). www.nobelprize.org/uploads/2021/10/advanced-chemistryprize2021-3.pdf
   Google Scholar
• Seeman JI. The Woodward–Doering/Rabe–Kindler total synthesis of quinine: setting the record straight. Angew. Chem. Int. Ed. 46(9), 1378–1413 (2007).
   PubMed Web of Science ®Google Scholar
• Jacques J, Collet A, Wilen SH. Enantiomers, Racemates and Resolutions. Wiley & Sons, NY, USA, 254, 257 (1981).
   Google Scholar
• Kacprzak K, Gawronski J. Resolution of racemates and enantioselective analytics by Cinchona alkaloids and their derivatives. In: Cinchona Alkaloids in Synthesis and Catalysis: Ligands, Immobilization and Organocatalysis.Song CE (Ed.). Wiley-VCH, Weinheim, Germany, 421–469 (2009).
   Google Scholar
• Boratyński PJ, Zielińska-Błajet M, Skarżewski J. Cinchona alkaloids – derivatives and applications. In: The Alkaloids: Chemistry and Biology (Volume 82).Knölker H-J (Ed.)., Elsevier, Amsterdam, The Netherlands, 29–145 (2019).
   Google Scholar
• Seeman JI. Revolutions in chemistry: assessment of six 20th century candidates (the instrumental revolution; Hückel molecular orbital theory; Hückel’s 4n + 2 rule; the Woodward–Hoffmann rules; quantum chemistry; and retrosynthetic analysis). JACS Au 3(9), 2378–2401 (2023).
   PubMedGoogle Scholar
• WHO. WHO model list of essential medicines – 22nd list (2021). www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.02
   Google Scholar
• WHO Expert Committee on the Selection of Essential Drugs & World Health Organization. The selection of essential drugs: report of a WHO expert committee [meeting held in Geneva from 17 to 21 October 1977] (1977). https://apps.who.int/iris/handle/10665/41272
   Google Scholar
• Baum RM. Top pharmaceuticals: a look at drugs that changed our world. Chem. Eng. News 83(25), 5 (2005).
   Google Scholar
• Dr Reddy’s Laboratories (UK) Limited & Others v Warner-Lambert Company LLC. [2023]EWCA Civ 73 (2023). www.bailii.org/ew/cases/EWCA/Civ/2023/73.pdf
   Google Scholar
• Gatti M, De Ponti F. Drug repurposing in the COVID-19 era: insights from case studies showing pharmaceutical peculiarities. Pharmaceutics 13(3), 302–322 (2021).
   PubMed Web of Science ®Google Scholar
• Pushpakom S, Iorio F, Eyers PA et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18(1), 41–58 (2019).
   PubMed Web of Science ®Google Scholar
• Breckenridge A, Jacob R. Overcoming the legal and regulatory barriers to drug repurposing. Nat. Rev. Drug Discov. 18(1), 1–2 (2019).
   PubMed Web of Science ®Google Scholar
• Saxena SK (Ed.). Drug Repurposing – Molecular Aspects and Therapeutic Applications. IntechOpen, London, UK (2022).
   Google Scholar
• Rudrapal M (Ed.). Drug Repurposing – Advances, Scopes and Opportunities in Drug Discovery. IntechOpen, London, UK (2023).
   Google Scholar
• Mulryne J. Second medical use: a regulatory perspective. Life Sciences Intellectual Property Review (2021). www.lifesciencesipreview.com/article/second-medical-use-a-regulatory-perspective
   Google Scholar
• Agranat I, Marom H. In defense of secondary pharmaceutical patents in drug discovery and development. ACS Med. Chem. Lett. 11(2), 91–98 (2020).
   PubMed Web of Science ®Google Scholar
• Agranat I, Caner H. Intellectual property and chirality of drugs. Drug Discov. Today 4(7), 313–321 (1999).
   PubMed Web of Science ®Google Scholar
• Agranat I, Caner H, Caldwell J. Putting chirality to work: the strategy of chiral switches. Nat. Rev. Drug Discov. 1(10), 753–768 (2002).
   PubMed Web of Science ®Google Scholar
• Rouhi AM. Chirality at work. Chem. Eng. News 81(18), 56–61 (2003).
   Web of Science ®Google Scholar
• Agranat I, Wainschtein SR. The strategy of enantiomer patents of drugs. Drug Discov. Today 15(5–6), 163–170 (2010).
   PubMed Web of Science ®Google Scholar
• Browne WR, Feringa BL. Chiroptical molecular switches. In: Molecular Switches (Second Edition) (Volume 1).Feringa BL, Browne WR (Eds). Wiley-VCH, Weinheim, Germany, 121–179 (2011).
   Google Scholar
• Baglai I, Leeman M, Bernard Kaptein B, Kellogg RM, Noorduin WL. A chiral switch: balancing between equilibrium and non-equilibrium states. Chem. Commun. 55, 6910–6913 (2019).
   PubMed Web of Science ®Google Scholar
• Anonymous. A new twist on the chiral switch. Nat. Rev. Drug Discov. 2(6), 424 (2003).
   PubMed Web of Science ®Google Scholar
• D’Acquarica I, Agranat I. The quest for secondary pharmaceuticals: drug repurposing/chiral-switches combination strategy. ACS Pharmacol. Transl. Sci. 6(2), 201–219 (2023).
   PubMedGoogle Scholar
• Aventis Pharma Deutschland GMBH & King Pharmaceuticals, Inc. v. Lupin, LTD, CAFC 2006–1530 (11 September 2007). https://cafc.uscourts.gov/opinions-orders/06-1530.pdf
   Google Scholar
• Warhurst DC, Craig JC, Adagu IS, Meyer DJ, Lee SY. The relationship of physico-chemical properties and structure to the differential antiplasmodial activity of the cinchona alkaloids. Malar. J. 2, 26–39 (2003).
   PubMed Web of Science ®Google Scholar
• Kacprzak KM. Chemistry and biology of Cinchona alkaloids. In: Natural Products.Ramawat KG, Mérillon JM (Eds). Springer-Verlag, Berlin Heidelberg, Germany, 605–641 (2013).
   Google Scholar
• Woodward RB, Cava MP, Ollis WD, Hunger A, Daeniker HU, Schenker K. The total synthesis of strychnine. Tetrahedron 19(2), 247–288 (1963).
   Web of Science ®Google Scholar
• Eliel EL, Wilen SH, Mander LN. Stereochemistry of Organic Compounds. John Wiley & Sons, NY, USA (1994).
   Google Scholar
• Caner H, Groner E, Levy L, Agranat I. Trends in the development of chiral drugs. Drug Discov. Today 9(3), 105–110 (2004).
   PubMed Web of Science ®Google Scholar
• Hutt AJ, Valentová J. The chiral switch: the development of single enantiomer drugs from racemates. Acta Fac. Pharm. Univ. Comen. 50, 7–23 (2003).
   Google Scholar
• Calcaterra A, D’Acquarica I. The market of chiral drugs: chiral switches versus de novo enantiomerically pure compounds. J. Pharm. Biomed. Anal. 147, 323–340 (2018).
   PubMed Web of Science ®Google Scholar
• Agranat I, Wainschtein SR, Zusman EZ. The predicated demise of racemic new molecular entities is an exaggeration. Nat. Rev. Drug Discov. 11(12), 972–973 (2012).
   PubMed Web of Science ®Google Scholar
• Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, Schutjens M-H. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov. Today 20(8), 1027–1034 (2015).
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Investigational drug. NCI’s dictionary of cancer terms (2022). www.cancer.gov/publications/dictionaries/cancer-terms/def/investigational-drug
   Google Scholar
• Kaufman TS, Rúveda EA. The quest for quinine: those who won the battles and those who won the war. Angew. Chem. Int. Ed. 44(6), 854–885 (2005).
   PubMed Web of Science ®Google Scholar
• Eyal S. The fever tree: from malaria to neurological diseases. Toxins 10(12), 491–502 (2018).
   PubMed Web of Science ®Google Scholar
• Gachelin G, Garner P, Ferroni E, Tröhler U, Chalmers I. Evaluating Cinchona bark and quinine for treating and preventing malaria. J. R. Soc. Med. 110(1), 31–40 (2017).
   PubMed Web of Science ®Google Scholar
• US FDA. Qualaquin, new drug application (NDA): 021799 (12 August 2005). www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021799s000TOC.cfm
   Google Scholar
• Achan J, Talisuna AO, Erhart A et al. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malar. J. 10, 144–155 (2011).
   PubMed Web of Science ®Google Scholar
• Wisniak J. Nicolas-Jean-Baptiste-Gaston Guibourt. Educ. Quimica 27, 163–171 (2016).
   Google Scholar
• Bussy AAB, Guibourt N-J-B-G. Observations relatives à la quinidine. J. Pharm. Chim. 22, 401–415 (1852).
   Google Scholar
• Pasteur L. Recherches sur les alcaloïdes des quinquinas. Compt. Rend. Acad. Sci. Tome 37, 110–114 (1853).
   Google Scholar
• Debrè P. Translated by Elborg Forster. Louis Pasteur. The Johns Hopkins University Press, MD, USA, 70–73 (1998).
   Google Scholar
• Levy RL. Clinical studies of quinidin. IV. The clinical toxicology of quinidin. JAMA 79(14), 1108–1113 (1921).
   Google Scholar
• Dymock W, Warden CJH, Hooper DA. History of the principal drugs of vegetable origin, met with in British India. In: Pharmacographia Indica Volume II. Kegan Paul, Trench, Trübner & Co., London, UK, 180–181 (1891).
   Google Scholar
• Sanders JP, Dawson WT. Efficacy of quinidine in malaria. JAMA 99(21), 1773–1777 (1932).
   Google Scholar
• Fletcher W. The relative efficiency of quinine and quinidine in the treatment of malaria. In: Medical Research Council: Clinical Comparisons of Quinine and Quinidine. His Majesty’s Stationery Office, London, UK, 17–27 (1925).
   Google Scholar
• Bozic B, Uzelac TV, Kezic A, Bajcetic M. The role of quinidine in the pharmacological therapy of ventricular arrhythmias ‘quinidine’. Mini Rev. Med. Chem. 18(6), 468–475 (2018).
   PubMed Web of Science ®Google Scholar
• Wenckebach KF. Cinchona derivatives in the treatment of heart disorders. JAMA 81(6), 472–474 (1923).
   Google Scholar
• Smulyan H. The beat goes on: the story of five ageless cardiac drugs. Am. J. Med. Sci. 356(5), 441–450 (2018).
   PubMed Web of Science ®Google Scholar
• US FDA. Certain antiarrhythmic drugs containing quinidine hydrochloride, isoproterenol hydrochloride, procainamide hydrochloride, quinidine polygalacturonate, quinidine sulfate, or quinidine gluconate. Federal Register 37(175), 18227–18229 (8 September 1972). www.govinfo.gov/content/pkg/FR-1972-09-08/pdf/FR-1972-09-08.pdf
   Google Scholar
• US FDA. New drug applications; notice of withdrawal of approval. Federal Register 38(22), 3208 (2 February 1973). www.govinfo.gov/content/pkg/FR-1973-02-02/pdf/FR-1973-02-02.pdf
   Google Scholar
• US FDA. Quinidine Gluconate Injection, New drug application (NDA): 007529 (12 July 1950). www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=007529
   Google Scholar
• US FDA. New drugs, reports of information for drug effectiveness. Federal Register 31(132), 9426 (9 July 1966). www.govinfo.gov/content/pkg/FR-1966-07-09/pdf/FR-1966-07-09.pdf
   Google Scholar
• US FDA. Certain antiarrhythmic drugs containing quinidine hydrochloride; quinidine gluconate; or procainamide hydrochloride. Federal Register 41(182), 40207–40209 (17 September 1976). www.govinfo.gov/content/pkg/FR-1976-09-17/pdf/FR-1976-09-17.pdf.
   Google Scholar
• US FDA. NDA classification codes. Manual of Policies and Procedures MAPP 5018.2 (8 December 2022). www.fda.gov/media/94381/download
   Google Scholar
• Centers for Disease Control and Prevention. Intravenous quinidine gluconate in the treatment of severe Plasmodium falciparum infections. MMWR Morb. Mortal. Wkly Rep. 34(24), 371 (1985).
   PubMedGoogle Scholar
• National Cancer Institute. Investigational new drug. NCI’s dictionary of cancer terms (2022). www.cancer.gov/publications/dictionaries/cancer-terms/def/investigational-new-drug
   Google Scholar
• Kitchen LW, Vaughn DW, Skillman DR. Role of US military research programs in the development of US Food and Drug Administration-approved antimalarial drugs. Clin. Infect. Dis. 43(1), 67–71 (2006).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Treatment with quinidine gluconate of persons with severe Plasmodium falciparum malaria: discontinuation of parenteral quinine. MMWR Recomm. Rep. 40(RR-4), 21–23 (1991).
   PubMedGoogle Scholar
• US FDA. Artesunate, New Drug Application (NDA): 213036 (26 May 2020). www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213036Orig1s000MultidisciplineR.pdf
   Google Scholar
• WHO. Guidelines for the treatment of malaria (third edition) (2015). https://apps.who.int/iris/bitstream/handle/10665/162441/9789241549127_eng.pdf?sequence=1
   Google Scholar
• United States Pharmacopoeia. Quinidine Systemic. USP Di 1997: Drug Information for the Health Care Professional (17th Edition, Volume 1). United States Pharmacopeial Convention, Rockville, MD, USA, 2493 (1997).
   Google Scholar
• US FDA. Withdrawal of approval of 25 new drug applications. Federal Register 84(174), 47309–47310 (9 September 2019). www.govinfo.gov/content/pkg/FR-2019-09-09/pdf/FR-2019-09-09.pdf
   Google Scholar
• Alpern JD, Dunlop SJ, Stauffer WM. Broken drug markets in infectious diseases: opportunities outside the private sector? PLoS Negl. Trop. Dis. 13(4), e0007190 (2019).
   PubMed Web of Science ®Google Scholar
• US FDA. Eli Lilly and Co. et al.; Withdrawal of approval of 25 new drug applications. Federal Register 84(174), 47309–47310 (9 September 2019). www.govinfo.gov/content/pkg/FR-2019-09-09/pdf/FR-2019-09-09.pdf
   Google Scholar
• US FDA. Quinidex, New Drug Application (NDA): 012796 (21 February 1962). www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012796
   Google Scholar
• US Patent and Trademark Office. Quinidex Extentabs: trademark registration no. 773526 US Trademark Electronic Search System (TESS) (1964). https://tsdr.uspto.gov/#caseNumber=72182504&caseSearchType=US_APPLICATION&caseType=DEFAULT&searchType=statusSearch
   Google Scholar
• US Patent and Trademark Office. Quinidex: trademark registration no. 2639478 US Trademark Electronic Search System (TESS) (2002). https://tsdr.uspto.gov/#caseNumber=76368261&caseSearchType=US_APPLICATION&caseType=DEFAULT&searchType=statusSearch
   Google Scholar
• US FDA. Lederle Laboratories et al.; Withdrawal of approval of 73 new drug applications and 62 abbreviated new drug applications. Federal Register 72(215), 62858–62863 (7 November 2007). www.govinfo.gov/content/pkg/FR-2007-11-07/pdf/FR-2007-11-07.pdf
   Google Scholar
• US FDA. Cardioquin, New Drug Application (NDA): 011642/S-012 (16 June 1999). www.accessdata.fda.gov/drugsatfda_docs/nda/99/11-642s012_Cardioquin.cfm
   Google Scholar
• US FDA. Nuedexta, New Drug Application (NDA): 021879 (29 October 2010). www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021879Orig1s000TOC.cfm
   Google Scholar
• Morris H, Wallach J. From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Test. Anal. 6(7–8), 614–632 (2014).
   PubMed Web of Science ®Google Scholar
• US FDA. Status of certain additional over-the-counter drug category II and III active ingredients. Federal Register 58(88), 27636–27644 (10 May 1993). www.govinfo.gov/app/details/FR-1993-05-10
   Google Scholar
• US FDA. Drug products containing quinine for the treatment and/or prevention of malaria for over-the-counter human use. Federal Register 60(75), 19650–19655 (19 April 1995). www.govinfo.gov/content/pkg/FR-1995-04-19/pdf/FR-1995-04-19.pdf
   Google Scholar
• US FDA. Drug products containing quinine for the treatment and/or prevention of malaria for over-the-counter human use. Federal Register 63(54), 13526–13529 (20 March 1998). www.govinfo.gov/content/pkg/FR-1998-03-20/pdf/FR-1998-03-20.pdf
   Google Scholar
• US FDA. Drug products containing quinine; enforcement action dates. Federal Register 71 (241), 75557–75560 (15 December 2006). https://www.govinfo.gov/content/pkg/FR-2006-12-15/pdf/FR-2006-12-15.pdf
   Google Scholar
• US FDA. Coartem, New Drug Application (NDA): 022268 (27 April 2009). www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000TOC.cfm
   Google Scholar
• US FDA. Termination of the Food and Drug Administration’s unapproved drugs initiative; request for information regarding drugs potentially generally recognized as safe and effective; withdrawal. Federal Register 86(101), 28605–28608 (27 May 2021). www.govinfo.gov/content/pkg/FR-2021-05-27/pdf/FR-2021-05-27.pdf
   Google Scholar
• Base de Données Publique des Médicaments. QUINIMAX 500 mg, comprimé sécable pelliculé – résumé des caractéristiques du produit (2022). https://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=69713550&typedoc=R
   Google Scholar
• Achan J, Byarugaba J, Barennes H, Tumwine JK. Rectal versus intravenous quinine for the treatment of childhood cerebral malaria in Kampala, Uganda: a randomized, double-blind clinical trial. Clin. Infect. Dis. 45(11), 1446–1452 (2007).
   PubMed Web of Science ®Google Scholar
• European Union Intellectual Property Network. Quinimax: registered trademark no. 4484186, France (11 January 2019). www.tmdn.org/tmview/#/tmview/detail/FR500000004484186
   Google Scholar
• Brewster JH. Racemic, scalemic, holemic. Chem. Eng. News 70(20), 2–3 (1992).
   Web of Science ®Google Scholar
• Eliel EL. Infelicitous stereochemical nomenclature. Chirality 9(5–6), 428–430 (1997).
   Web of Science ®Google Scholar
• Han J, Kitagawa O, Wzorek A, Klika KD, Soloshonok VA. The self-disproportionation of enantiomers (SDE): a menace or an opportunity? Chem. Sci. 9, 1718–1739 (2018).
   PubMed Web of Science ®Google Scholar
• Shiomi S, Misaka R, Kaneko M, Ishikawa H. Enantioselective total synthesis of the unnatural enantiomer of quinine. Chem. Sci. 10(41), 9433–9437 (2019).
   PubMed Web of Science ®Google Scholar
• Somberg JC, Ranade V. Optically active isomers of quinine and quinidine and their respective biological action. US Patent 6,844,355 B2, 2005; expired 2009.
   Google Scholar
• Somberg JC, Ranade V. Optically active isomers of quinine and quinidine and their respective biological action. EP Patent 1,240,167 A1, EP Patent Application 00986731.8, 2003. Refused 2006.
   Google Scholar
• EP Examining Division. Patent Application EP 00986731.8. Global Register, Grounds for the decision to refuse the application (Annex) (3 July 2006). https://register.epo.org/application?number=EP00986731&lng=en&tab=doclist
   Google Scholar
• Caner H. Chiral Switches of Drugs. Ph.D. Thesis, The Hebrew University of Jerusalem, Jerusalem, Israel, 157–160 (2005).
   Google Scholar
• Solary E, Caillot D, Chauffert B et al. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J. Clin. Oncol. 10(11), 1730–1736 (1992).
   PubMed Web of Science ®Google Scholar
• Hamed AR, Abdel-Azim NS, Shams KA, Hammouda FM. Targeting multidrug resistance in cancer by natural chemosensitizers. Bull. Natl Res. Cent. 43, 8 (2019).
   Google Scholar
• Agranat I, Staring GJ, Wynberg H. Quinine and quinidine: a model for diastereomeric interactions. Collection of Papers and Abstracts of: International Symposium on New Drug Research and Development. Beijing, China, 22–25 October 1991.
   Google Scholar
• Pirkle WH, Hoover DJ. NMR chiral solvating agents. Top. Stereochem. 13, 263–331 (1982).
   Google Scholar
• Williams T, Pitcher RG, Bommer P, Gutzwiller J, Uskoković M. Diastereomeric solute–solute interactions of enantiomers in achiral solvents. Nonequivalence of the nuclear magnetic resonance spectra of racemic and optically active dihydroquinine. J. Am. Chem. Soc. 91(7), 1871–1872 (1969).
   Web of Science ®Google Scholar
• Marom H, Pogodin S, Agranat I. Single enantiomer versus racemate: chiral distinction in the proton pump inhibitors omeprazole and esomeprazole. Chirality 26(4), 214–227 (2014).
   PubMed Web of Science ®Google Scholar
• Hariyanti H, Mauludin R, Sumirtapura YC, Kurniati NF. A review: pharmacological activities of quinoline alkaloid of Cinchona sp. Biointerface Res. Appl. Chem. 13(4), 319–331 (2023).
   Web of Science ®Google Scholar
• Agius N, Magri DC. Cinchona alkaloids – acid, anion-driven fluorescent INHIBIT logic gates with a receptor1-fluorophore-spacer-receptor2 format and PET and ICT mechanisms. RSC Adv. 13, 13505–13510 (2023).
   PubMed Web of Science ®Google Scholar
• Warner-Lambert Company LLC v Generics (UK) Ltd t/a Mylan and another, UKSC 56 (14 November 2018). www.supremecourt.uk/cases/docs/uksc-2016-0197-judgment.pdf
   Google Scholar
• Spenner JM. Obvious-to-try obviousness of chemical enantiomers in view of pre- and post-KSR analysis. J. Pat. Trademark Off. Soc’y 90(7), 475–515 (2008).
   Google Scholar
• Gorka AP, Sherlach KS, de Dios AC, Roepe PD. Relative to quinine and quinidine, their 9-epimers exhibit decreased cytostatic activity and altered heme binding but similar cytocidal activity versus Plasmodium falciparum. Antimicrob. Agents Chemother. 57(1), 365–374 (2013).
   PubMed Web of Science ®Google Scholar
• Correa CM. Guidelines for Pharmaceutical Patent Examination: Examining Pharmaceutical Patents from a Public Health Perspective United Nations Development Programme, NY, USA (2015).
   Google Scholar
• Malik JA, Ahmed S, Momin SS et al. Drug repurposing: a new hope in drug discovery for prostate cancer. ACS Omega 8(1), 56–73 (2023).
   PubMed Web of Science ®Google Scholar